If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine injection)
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Always check insulin labels before administration.1
Instruct patients on proper use and injection technique before initiating Basaglar.1
Visually inspect the Basaglar Pen for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.1
Inject between 1 and 80 units of Basaglar per injection.1
Administer Basaglar subcutaneously into the abdominal area, thigh, or deltoid.1
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.1
Do not dilute or mix Basaglar with any other insulin or solution as the onset of action or time to peak effect of Basaglar and the mixed insulin may be altered in an unpredictable manner.1
Do not administer Basaglar intravenously or via an insulin pump because this could result in severe hypoglycemia.1
Dosing Instructions
In patients with T1DM, use Basaglar concomitantly with short–acting insulin.1
Inject Basaglar subcutaneously once daily at any time of day but at the same time every day.1
Individualize and titrate the dosage of Basaglar based on the individual’s
metabolic needs
BG monitoring results
glycemic control goal
type of DM, and
prior insulin use.1
Perform dosage adjustments of Basaglar under medical supervision and with appropriate glucose monitoring. Dosage adjustments may be needed with
changes in physical activity
changes in meal patterns, such as with macronutrient content or timing of food intake
episodes of acute illness, or
changes in renal or hepatic function.1
Enclosed Prescribing Information
BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly
1. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
Basaglar = Basaglar® (insulin glargine injection) 100 units/mL
BG = blood glucose
DM = diabetes mellitus
Pen = KwikPen®
T1DM = type 1 diabetes mellitus
Date of Last Review: July 22, 2019
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST